Organon & Company
Research Organon & Company (OGN) on Bullrun: valuation model: fairly valued, market cap USD 3.56B, P/E 14.4, dividend yield 0.6%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOGN
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signalfairly valued
- Market capUSD 3.56B
- P/E14.4
- Dividend yield0.6%
- Financial periodFY2025
- RevenueUSD 6.22B
- Revenue growth-2.9%
- Net incomeUSD 187.00M
- Free cash flowUSD 538.00M
- Gross margin53.3%
Valuation Snapshot
Bullrun's latest valuation model marks Organon & Company as fairly valued; latest market cap is USD 3.56B; P/E is 14.4; dividend yield is 0.6%.
About Organon & Company
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy;
Frequently asked questions
Is Organon & Company overvalued or undervalued?
Bullrun's valuation model currently marks Organon & Company as fairly valued.
What is Organon & Company's market cap?
Organon & Company's market capitalization is USD 3.56B.
What is Organon & Company's P/E ratio?
Organon & Company's price-to-earnings (P/E) ratio is 14.4.
Does Organon & Company pay a dividend?
Organon & Company has a dividend yield of 0.6%.
What does Organon & Company do?
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.